A fistful of T cells

British Journal of Rheumatology

Volumn 37, Issue 6, 1998, Pages 602-611

  Moots, R J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antigen presentation; Autoimmune disease; Collagen; Peptide; Rheumatoid arthritis; T cells

Indexed keywords

AMINO ACID; AUTOANTIGEN; BETA 2 MICROGLOBULIN; COLLAGEN TYPE 2; EPITOPE; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; VIRUS PROTEIN;

ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOLECULAR MIMICRY; MULTIPLE SCLEROSIS; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; T LYMPHOCYTE;

EID: 0031926504     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/37.6.602     Document Type: Article

References (47)

1. Fox DA. The role of T cells in the immunopathogenesis of rheumatoid arthritis. Arthritis Rheum 1997;40:598-609.
2. Vaughan JH, Fox RI, Abresch RJ, Tsoukas CD, Curd JG, Carson DA. Thoracic duct drainage in rheumatoid arthritis. Clin Exp Immunol 1984;58:645-53.
3. Helfgott SM. Total lymphoid irradiation. Rheum Dis Clin North Am 1989;15:577-82.
4. Wilder RL, Yarboro CH, Decker JL. The effects of repeated leukapheresis in patients with severe refractory rheumatoid arthritis. Prog Clin Biol Res 1982;106:49-59.
5. Choy EH, Panayi GS, Kingsley GH. Therapeutic monoclonal antibodies. Br J Rheumatol 1995;34:707-15.
6. Forre O. Cyclosporine in rheumatoid arthritis: an overview. Clin Rheumatol 1995;14(suppl. 2):33-6.
7. Gough A, Faint J, Salmon M et al. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 1994;37:1166-70.
8. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987;30:1205-13.
9. Salmon M, Wordsworth P, Emery P, Tunn E, Bacon PA, Bell JI. The association of HLA DR beta alleles with self-limiting and persistent forms of early symmetrical polyarthritis. Br J Rheumatol 1993;32:628-30.
10. Moots RJ. In the groove: the fine detail of antigen presentation by HLA-A2 to cytotoxic T lymphocytes. Clin Sci 1993;84:585-91.
11. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol 1979;27:51-177.
12. Townsend AR, Gotch FM, Davey J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 1985;42:457-67.
13. Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986;44:959-68.
14. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329:506-12.
15. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987;329:512-8.
16. Morrison J, Elvin J, Latron F et al. Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes. Eur J Immunol 1992;22:903-7.
17. Moots RJ, Samberg NL, Pazmany L, Frelinger JA, McMichael AJ, Stauss HJ. A cross-species functional interaction between the murine major histocompatibility complex class I alpha 3 domain and human CD8 revealed by peptide-specific cytotoxic T lymphocytes. Eur J Immunol 1992;22:1643-6.
18. Moots RJ, Matsui M, Pazmany L, McMichael AJ, Frelinger JA. A cluster of mutations in HLA-A2 α-helix abolishes peptide recognition by T cells. Immunogenetics 1991; 34:141-8.
19. Lombardi G, Matsui M, Moots RJ et al. Limited regions of the α2 domain α helix control anti-A2 allorecognition. An analysis using a panel of A2-mutants. Immunogenetics 1991;34:149-56.
20. Lombardi G, Matsui M, Moots RJ et al. Structural relationship between HLA-A2-restricted and anti-A2 allospecific T-cell recognition. Analysis by mutation of the codons for polymorphic and conserved residues. Transplant Proc 1991;23:444-8.
21. Moots RJ. The fine specificity of antigen recognition by HLA-A0201-restricted cytotoxic T lymphocytes. PhD Thesis, Institute of Molecular Medicine, Oxford University, 1992.
22. Townsend A, Elliott T, Cerundolo V, Foster L, Barber B, Tse A. Assembly of MHC class I molecules analyzed in vitro. Cell 1990;62:285-95.
23. Latron F, Pazmany L, Morrison J et al. A critical role for conserved residues in the cleft of HLA-A2 in presentation of a nonapeptide to T cells. Science 1992;257:964-7.
24. Matsui M, Moots RJ, McMichael AJ, Frelinger J. Significance of the six peptide binding pockets of HLA-A2.1 in influenza A matrix peptide-specific CTL reactivity. Hum Immunol 1994;41:160-6.
25. Matsui M, Moots RJ, Warburton RJ et al. Genetic evidence for differences between intracellular and extra-cellular peptides in influenza A matrix peptide-specific CTL recognition. J Immunol 1995;154:1088-96.
26. Moots RJ, Frelinger J, Strominger JL, McMichael AJ. The precise localisation of a peptide in the cleft of HLA-A0201. Clin Rheumatol 1992;11:150-1.
27. Zhang W, Young AC, Imarai M, Nathenson SG, Sacchettini, JC. Crystal structure of the major histocompatibility complex class I H-2Kb molecule containing a single viral peptide: implications for peptide binding and T-cell receptor recognition. Proc Natl Acad Sci USA 1992;89:8403-7.
28. Moots RJ, Wucherpfennig KW. The role of T cells in autoimmunity. In: Gaston JSH, ed. Immunological aspects of rheumatic disease. Cambridge: Cambridge University Press, 1998; in press.
29. Wucherpfennig KW, Zhang J, Witek C et al. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 1994;152:5581-92.
30. Robinson JH, Kehoe MA. Group A streptococcal M proteins: Virulence factors and protective antigens. Immunol Today 1992;13:362-7.
31. Bhardwaj V, Kumar V, Geysen HM, Sercarz EE. Degenerate recognition of a dissimilar antigenic peptide by myelin basic protein-reactive T cells. Implications for thymic education and autoimmunity. J Immunol 1993;151:5000-10.
32. Wucherpfennig KW, Sette A, Southwood S et al. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med 1994;179:279-90.
33. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695-705.
34. Moots RJ, Young SP. Antigen processing and major histocompatibility complex function in T lymphocyte responses. In: Stockley R, ed. Host defences in respiratory disease. London: John Wiley, 1997:100-28.
35. Staines NA, Wooley PH. Collagen arthritis - what can it teach us. Br J Rheumatol 1994;33:798-807.
36. Trentham DE, Dynesius-Trentham RA, Orav EJ et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993;261:1727-30.
37. Londei M, Savill CM, Verhoef A et al. Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci USA 1989;86:636-40.
38. Brown JH, Jardetzky TS, Gorga JC et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993;364:33-9.
39. Stern LJ, Brown JH, Jardetzky TS et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994;368:215-21.
40. Hammer J, Bono E, Gallazzi F, Belunis C, Nagy Z, Sinigaglia F. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med 1994;180:2353-8.
41. Hammer J, Gallazzi F, Bono E et al. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med 1995;181:1847-55.
42. Sinigaglia F, Hammer J. Defining rules for the peptide-MHC class II interaction. Curr Opin Immunol 1994;6:52-6.
43. Fugger L, Rothbard JB, Sonderstrup-McDevitt G. Specificity of an HLA-DRB1*0401-restricted T cell response to type II collagen. Eur J Immunol 1996;26:928-33.
44. Rosloniec EF, Brand DD, Myers LK et al. An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. J Exp Med 1997;185:1113-22.
45. Michaelsson E, Andersson M, Engstrom A, Holmdahl R. Identification of an immunodominant type-II collagen peptide recognized by T cells in H-2q mice: self tolerance at the level of determinant selection. Eur J Immunol 1992;22:1819-25.
46. Brocke S, Gijbels K, Allegretta M et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996;379:343-6.
47. Myers LK, Rosloniec EF, Seyer JM, Stuart JM, Kang AH. Design of a synthetic peptide capable of treating collagen-induced arthritis via MHC blockade. Arthritis Rheum 1992;35:51-51.